This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
5-Hydroxytryptophan: Difference between revisions
>Oskykins |
>Oskykins |
||
| Line 12: | Line 12: | ||
Combinations in the list below may increase the amount of neurotransmitters, such as serotonin, to dangerous or even fatal levels, resulting in life-threatening [[serotonin syndrome]]. | Combinations in the list below may increase the amount of neurotransmitters, such as serotonin, to dangerous or even fatal levels, resulting in life-threatening [[serotonin syndrome]]. | ||
*'''[[DangerousInteraction::Selective serotonin re-uptake inhibitors]] (SSRIs)''' - When combined with antidepressants of the SSRI class, high doses of 5-HTP can cause acute serotonin syndrome in rats. | *'''[[DangerousInteraction::Selective serotonin re-uptake inhibitors]] (SSRIs)''' - When combined with antidepressants of the SSRI class, high doses of 5-HTP can cause acute serotonin syndrome in rats.<ref name="one">https://www.ncbi.nlm.nih.gov/pubmed/18499101 | Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats.</ref><ref name="one">https://www.ncbi.nlm.nih.gov/pubmed/16488409 | Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats.</ref> | ||
*'''[[DangerousInteraction::Serotonin releasers]]''' such as '''[[MDMA]]''', '''[[4-FA]]''', '''[[MDAI]]''' and '''[[αMT]]''' - To prevent serotonin syndrome, 5-HTP should only be taken once the user has come down from the MDMA (or other serotonin releaser), roughly 12 hours after the last dose. | *'''[[DangerousInteraction::Serotonin releasers]]''' such as '''[[MDMA]]''', '''[[4-FA]]''', '''[[MDAI]]''' and '''[[αMT]]''' - To prevent serotonin syndrome, 5-HTP should only be taken once the user has come down from the MDMA (or other serotonin releaser), roughly 12 hours after the last dose. | ||
*'''[[DangerousInteraction::MAOIs]]''' such as '''[[syrian rue]]''', '''[[banisteriopsis caapi]]''', '''[[2C-T-2]]''', '''[[2C-T-7]]''', '''[[αMT]]''', and some '''[[antidepressants]]''' - When combined with antidepressants of the MAOI class, high doses of 5-HTP can cause acute serotonin syndrome in rats.<ref>https://www.ncbi.nlm.nih.gov/pubmed/18499101 | Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats.</ref><ref>https://www.ncbi.nlm.nih.gov/pubmed/16488409 | Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats.</ref> | *'''[[DangerousInteraction::MAOIs]]''' such as '''[[syrian rue]]''', '''[[banisteriopsis caapi]]''', '''[[2C-T-2]]''', '''[[2C-T-7]]''', '''[[αMT]]''', and some '''[[antidepressants]]''' - When combined with antidepressants of the MAOI class, high doses of 5-HTP can cause acute serotonin syndrome in rats.<ref name="one">https://www.ncbi.nlm.nih.gov/pubmed/18499101 | Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats.</ref><ref name="one">https://www.ncbi.nlm.nih.gov/pubmed/16488409 | Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats.</ref> | ||
*'''[[Tricyclic antidepressants (TCAs)]]''' | *'''[[Tricyclic antidepressants (TCAs)]]''' | ||
*'''[[DangerousInteraction::Tramadol]]''' | *'''[[DangerousInteraction::Tramadol]]''' | ||